J
Jessica Vermeulen
Researcher at Janssen Pharmaceutica
Publications - 93
Citations - 4876
Jessica Vermeulen is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Daratumumab & Ibrutinib. The author has an hindex of 23, co-authored 82 publications receiving 2967 citations. Previous affiliations of Jessica Vermeulen include Johnson & Johnson & Yıldırım Beyazıt University.
Papers
More filters
Journal ArticleDOI
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau,Michel Attal,Cyrille Hulin,Bertrand Arnulf,Karim Belhadj,Lotfi Benboubker,Marie C. Béné,Annemiek Broijl,Hélène Caillon,Denis Caillot,Jill Corre,Michel Delforge,Thomas Dejoie,Chantal Doyen,Thierry Facon,Cécile Sonntag,Jean Fontan,Laurent Garderet,Kon-Siong Jie,Lionel Karlin,Frédérique Kuhnowski,Jérôme J. Lambert,Xavier Leleu,Pascal Lenain,Margaret Macro,Claire Mathiot,Frédérique Orsini-Piocelle,Aurore Perrot,Anne-Marie Stoppa,Niels W.C.J. van de Donk,Soraya Wuilleme,Sonja Zweegman,Brigitte Kolb,Cyrille Touzeau,Murielle Roussel,Mourad Tiab,Jean-Pierre Marolleau,Nathalie Meuleman,Marie-Christiane Vekemans,Matthijs Westerman,Saskia K. Klein,Mark-David Levin,Jean Paul Fermand,Martine Escoffre-Barbe,Jean-Richard Eveillard,Reda Garidi,Tahamtan Ahmadi,Sen Zhuang,Christopher Chiu,Lixia Pei,Carla de Boer,Elena Smith,William Deraedt,Tobias Kampfenkel,Jordan M. Schecter,Jessica Vermeulen,Hervé Avet-Loiseau,Pieter Sonneveld +57 more
TL;DR: D-VTd before and after autologous stem-cell transplantation improved depth of response and progression-free survival with acceptable safety and CASSIOPEIA is the first study showing the clinical benefit of daratumumab plus standard of care in transplant-eligible patients with newly diagnosed multiple myeloma.
Journal ArticleDOI
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
Martin Dreyling,Wojciech Jurczak,Mats Jerkeman,Rodrigo Santucci Silva,Chiara Rusconi,Marek Trneny,Fritz Offner,Dolores Caballero,Cristina João,Mathias Witzens-Harig,Georg Hess,Isabelle Bence-Bruckler,Seok-Goo Cho,John Bothos,Jenna D. Goldberg,Christopher Enny,Shana Traina,Sriram Balasubramanian,Nibedita Bandyopadhyay,Steven Sun,Jessica Vermeulen,Aleksandra Rizo,Simon Rule +22 more
TL;DR: Ibrutinib treatment resulted in significant improvement in progression-free survival and better tolerability versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma, and lend further support to the positive benefit-risk ratio for ibrut inib in relapsedor refractors.
Journal ArticleDOI
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Peter M. Voorhees,Jonathan L. Kaufman,Jacob P. Laubach,Douglas W. Sborov,Brandi Reeves,Cesar Rodriguez,Ajai Chari,Rebecca Silbermann,Luciano J. Costa,Larry D. Anderson,Nitya Nathwani,Nina Shah,Yvonne A. Efebera,Sarah A. Holstein,Caitlin Costello,Andrzej Jakubowiak,Tanya M. Wildes,Robert Z. Orlowski,Kenneth H. Shain,Andrew J. Cowan,Sean Murphy,Yana Lutska,Huiling Pei,Jon Ukropec,Jessica Vermeulen,Carla de Boer,Daniela Hoehn,Thomas S. Lin,Paul G. Richardson +28 more
TL;DR: Daratumumab with RVd induction and consolidation improved depth of response in patients with transplant-eligible NDMM, with no new safety concerns.
Journal ArticleDOI
Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Jermaine Coward,Hagen Kulbe,Probir Chakravarty,David Leader,Vessela Vassileva,D. Andrew Leinster,Richard G. Thompson,Tiziana Schioppa,Jeffery Nemeth,Jessica Vermeulen,Naveena Singh,Norbert Avril,Jeffrey Cummings,Elton Rexhepaj,Karin Jirström,William M. Gallagher,Donal J. Brennan,Iain A. McNeish,Frances R. Balkwill +18 more
TL;DR: In this paper, the authors investigated whether inhibition of IL-6 has therapeutic activity in ovarian cancer via abrogation of a tumor-promoting cytokine network, and they combined pre-clinical and in silico experiments with a phase II clinical trial of the anti-IL-6 antibody siltuximab in patients with platinum-resistant ovarian cancer.
Journal ArticleDOI
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes,Laurie H. Sehn,Peter Johnson,Pier Luigi Zinzani,Xiaonan Hong,Jun Zhu,Caterina Patti,David Belada,Olga Samoilova,Cheolwon Suh,Sirpa Leppä,Shinya Rai,Mehmet Turgut,Wojciech Jurczak,Matthew C. Cheung,Ronit Gurion,Ronit Gurion,Su-Peng Yeh,Andres Lopez-Hernandez,Ulrich Dührsen,Catherine Thieblemont,C.S. Chiattone,Sriram Balasubramanian,Jodi Carey,Grace Liu,S. Martin Shreeve,Steven Sun,Sen Hong Zhuang,Jessica Vermeulen,Louis M. Staudt,Wyndham H. Wilson +30 more
TL;DR: The study did not meet its primary end point in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup, but in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety.